NCT06336018View on ClinicalTrials.gov

A Research Study on Etavopivat in Participants With and Without Liver Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions
Liver Diseases
Interventions
DRUG

Etavopivat

Participants will receive a single dose of etavopivat orally.

Trial Locations (3)

32806

Orlando Clinical Research Center, Orlando

32809

Orlando Clinical Research Center, Orlando

78215

Amer. Rrsch Corp-TX Liver Inst, San Antonio

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT06336018 - A Research Study on Etavopivat in Participants With and Without Liver Disease | Biotech Hunter | Biotech Hunter